A PHASE 1/2 OPEN-LABEL DOSE-ESCALATION SAFETY AND TOLERABILITY STUDY OF NC410 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Brief description of study
The purpose of the study is to determine the safety and tolerability of NC410, and to assess the preliminary efficacy of NC410 in subjects with advanced or metastatic solid tumors. We want to know the maximum tolerated dose of the study drug NC410. The study drug NC410 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.
Clinical Study Identifier: s20-01658
ClinicalTrials.gov Identifier: NCT04408599
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
